Interleukin (IL-2) Treatment

Led by one of the nation’s most experienced IL-2 oncologists, Dr. Gerald Miletello, our highly skilled medical team is dedicated to caring for patients undergoing PROLEUKIN® IL-2 therapy. IL-2 has been used for more than 15 years in the treatment of metastatic melanoma and for more than 20 years in the treatment of metastatic kidney cancer (renal cell carcinoma). Patient outcomes have surpassed national averages and we are creating success stories every day.

How IL-2 Therapy Works

Studies have shown that IL-2 therapy is effective for treating these cancers, which traditionally have low survival rates. A form of immunotherapy, IL-2 uses the body’s natural immune system to fight cancer, as opposed to chemotherapy, which directly attacks the cancer itself.

It is administered intravenously at the hospital and patients can go home once the injection therapy is complete. After your first course of IL-2 therapy, which takes about two months, our team of caregivers may be able to determine if your tumors have shrunk. Depending on your state of health and the success of the first course of treatment, a second course of therapy may be recommended.

IL-2 Treatment Center

Our cancer center includes spacious, private rooms appointed with wood floors, microwave, refrigerator and television. Newly added space for family members offers quiet accommodations for resting, reading or consulting with your loved one's team of caregivers. Our campus amenities include free valet parking, a full-service café, courtyards, coffee shop, pharmacy and gift shop.

Call (225) 237-1600 to speak with an expert who can answer your questions, address your concerns and provide support as you go through diagnosis, treatment and recovery.

Learn About Dr. Miletello

Baton Rouge General's regionally recognized IL-2 cancer treatment program is led by medical director Dr. Gerald Miletello. One of the most experienced IL-2 oncologists in the nation, Dr. Miletello has treated patients with IL-2 therapy since 2001. In a practice that spans more than 25 years, Dr. Miletello's outcomes with IL-2 therapy have surpassed the national averages and he has seen many success stories in his years of administering IL-2 treatment of metastatic melanoma and metastatic kidney cancer.

  • Board Certified in Internal Medicine
  • Member of the Southern Medical Society
  • Board Certified in Medical Oncology
  • Member of American College of Physicians
  • Member of East Baton Rouge Parish Medical Society
  • Graduate of LSU School of Medicine
  • Member of American Society of Clinical Oncology